Abstract
Suppression of the renin-angiotensin system (RAS) for decades is desired for the treatment of systemic arterial hypertension, due to its effects of vasoconstriction and increased blood pressure. Currently, various drugs are capable of performing such study, for example, telmisartan which is an angiotensin II (AT 1) type 1 receptor antagonist. The RAS also operates locally and its componen…